Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
PhaeochromocytomaParaganglioma
Interventions
DRUG

Vandetanib

100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle

RADIATION

131I-mIBG

Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)

Trial Locations (3)

Unknown

Guy's and St Thomas' NHS Foundation Trust, London

The Christie NHS Foundation Trust, London

University College London Hospitals NHS Foundation Trust, London

Sponsors
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

University College, London

OTHER